Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 44.05 M
The data is delayed by 15 minutes.
GALT is in the long-term up 324% in 3 years.
Description: Galectin Therapeutics Inc., a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The company?s lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trials in Europe as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was
|Shares Outstanding||28.98 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||2.02||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-51.72%||ROE||-54.05%||ROI|
|Current Ratio||23.21||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.05|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||4.53 M||Cash From Investing Activities||Cash From Operating Activities||-4.31 M||Gross Profit|
|Net Profit||-4.83 M||Operating Profit||-4.84 M||Total Assets||29.97 M||Total Current Assets||29.96 M|
|Total Current Liabilities||1.29 M||Total Debt||Total Liabilities||1.29 M||Total Revenue|
|High 52 week||9.16||Low 52 week||3.16||Last close||4.3||Last change||-1.83%|
|RSI||25.75||Average true range||0.3||Beta||0.39||Volume||315.59 K|
|Simple moving average 20 days||-8.61%||Simple moving average 50 days||-11.65%||Simple moving average 200 days||-13.96%|
|Performance Week||-9.47%||Performance Month||-13.65%||Performance Quart||-9.28%||Performance Half||-16.02%|
|Performance Year||27.6%||Performance Year-to-date||25.36%||Volatility daily||3.28%||Volatility weekly||7.34%|
|Volatility monthly||15.04%||Volatility yearly||52.09%||Relative Volume||998.23%||Average Volume||381.21 K|
|New High||New Low|
2019-05-27 08:44:11 | What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s NASDAQ:GALT?
2019-05-23 17:30:00 | Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering
2019-05-10 08:00:00 | Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
2019-03-06 11:34:20 | Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248%
2019-03-06 08:03:00 | Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
2019-03-06 08:00:00 | Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
2019-02-25 08:00:00 | Galectin Therapeutics to Present at Berenberg NASH Day in New York
2019-02-13 15:36:08 | Conatus CNAT Completes Enrollment in Phase II NASH Study
2019-02-13 09:53:02 | Ascendis Pharma Files IND for Hypoparathyroidism Candidate
2019-02-04 09:27:02 | Alkermes Sinks as FDA Refuses to Approve Depression Drug
2019-02-01 10:07:03 | AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA
2019-01-30 09:30:02 | Is Galectin Therapeutics GALT Stock Outpacing Its Medical Peers This Year?
2018-12-25 13:28:36 | Did Galectin Therapeutics, Inc. NASDAQ:GALT Insiders Sell Shares?
2018-12-20 08:30:00 | Galectin Therapeutics Announces Extension of $10 Million Line Credit
2018-11-27 08:15:00 | New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
2018-11-19 09:19:53 | Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
2018-11-05 08:37:01 | Implied Volatility Surging for Galectin Therapeutics GALT Stock Options
2018-10-11 07:30:00 | Market Trends Toward New Normal in Altra Industrial Motion, IDEXX Laboratories, BioTelemetry, Galectin Therapeutics, NETGEAR, and Merck & Co. — Emerging Consolidated Expectations, Analyst Ratings
2018-09-26 15:21:23 | 5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH
2018-09-21 10:43:02 | Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
2018-09-21 08:00:00 | Today's Research Reports on Trending Tickers: MiMedx Group and Galectin Therapeutics
2018-09-20 08:25:00 | Galectin stock lifts 15% premarket on early cancer combination trial results
2018-09-18 08:53:12 | Is the Options Market Predicting a Spike in Galectin Therapeutics GALT Stock?
2018-08-31 14:46:00 | Penny Stocks to Buy Using Technical Analysis for September 2018
2018-08-21 11:27:00 | 3 Marijuana Stocks & Biotech Stocks Capitalizing on Industry Momentum
2018-08-20 08:42:12 | Are Options Traders Betting on a Big Move in Galectin Therapeutics GALT Stock?
2018-08-03 07:30:00 | Market Trends Toward New Normal in Conn's, Herman Miller, TrueBlue, Brandywine Realty Trust, Tenneco, and Galectin Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
2018-07-26 08:57:00 | 3 Stocks That Could Double Your Money
2018-07-11 07:45:00 | Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks
2018-06-29 09:00:00 | Penny Stocks to Buy Using Technical Analysis
2018-06-27 12:56:00 | Why Galectin Therapeutics Stock Bolted Higher Today
2018-06-26 08:55:12 | Is the Options Market Predicting a Spike in Galectin Therapeutics GALT Stock?
2018-06-22 10:40:00 | Company Profile for Galectin Therapeutics Inc.
2018-06-17 16:17:00 | 2 Clinical-Stage Biotech Stocks That Could Soar Next Week
2018-06-17 10:37:49 | Market Sentiment Around Loss-Making Galectin Therapeutics Inc NASDAQ:GALT